OABI: OmniAb Corp EV/EBITDA Multiple

Symbol and logo of brand OmniAb (OABI)

OmniAb, Inc. (OABI) provides antibody discovery technologies via transgenic animals for major B2B partners, targeting the biotech development market. This chart shows the EV/EBITDA market valuation is 0.00. OmniAb, Inc. (OABI) monetizes its unique screening and database through licenses and royalties. Stable demand for pharmaceuticals makes the business a defensive asset that functions independently of global economic fluctuations.

OABI OmniAb Inc: Total Company Value to Operating Income Before Depreciation Ratio in the range 11/23/2025 - 11/16/2026

Analytical breakdowns for OmniAb, Inc.

- stock price and consensus target price:
Initial company analysis:OABI (omniab.com)
Original product of OmniAb

OmniAb, Inc. (OABI) utilizes AI platforms to accelerate antibody discovery, a process that requires significant capital expenditures. The company's current EV/EBITDA value illustrates the enterprise value, including debt, relative to operating profit. This metric determines the payback period for all assets, excluding the impact of taxes and depreciation. A decline in this ratio signals that the asset is undervalued, while a sharp increase warns of overheating quotes.